Articles liés à Drug Discovery in Cancer Epigenetics
Synopsis
Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
À propos des auteurs
Dr. Gerda Egger is an Associate Professor of Epigenetics at the Clinical Institute of Pathology, Medical University of Vienna.
Dr. Paola Barbara Arimondo is the Director of the Unité de Service et de Recherche (USR n°3388) entitled "Epigenetic Targeting of Cancer -ETaC-" which brings together basic and applied research - a joint laboratory of the Institut de Recherche Pierre Fabre (IRPF) and the CNRS. She is extremely experienced in researching regulatory pharmaceuticals and cancer epigenetics.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Acheter neuf
Afficher cet article
EUR 120,82
EUR 10,98 expédition depuis Royaume-Uni vers France
Destinations, frais et délaisRésultats de recherche pour Drug Discovery in Cancer Epigenetics
Image d'archives
Drug Discovery in Cancer Epigenetics (Translational Epigenetics Series)
Edité par
Academic Press 2016-02-05, 2016
ISBN 10 : 0128022086
ISBN 13 : 9780128022085
Neuf
Couverture rigide
Vendeur : Chiron Media, Wallingford, Royaume-Uni
Évaluation du vendeur 4 sur 5 étoiles
Hardcover. Etat : New. N° de réf. du vendeur 6666-ELS-9780128022085
Quantité disponible : Plus de 20 disponibles
Image d'archives
Drug Discovery in Cancer Epigenetics
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Évaluation du vendeur 5 sur 5 étoiles
Hardcover. Etat : Brand New. 1st edition. 498 pages. 9.50x8.00x1.00 inches. In Stock. N° de réf. du vendeur __0128022086
Quantité disponible : 2 disponible(s)
Image fournie par le vendeur
Drug Discovery in Cancer Epigenetics
Vendeur : moluna, Greven, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Etat : New. Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as bio. N° de réf. du vendeur 151151580
Quantité disponible : 1 disponible(s)
Image d'archives
Drug Discovery in Cancer Epigenetics
impression à la demandeVendeur : Brook Bookstore On Demand, Napoli, NA, Italie
Évaluation du vendeur 5 sur 5 étoiles
Etat : new. Questo è un articolo print on demand. N° de réf. du vendeur 8217d68e366f130cf6ec187fa1fb1b28
Quantité disponible : Plus de 20 disponibles
Image d'archives
Drug Discovery in Cancer Epigenetics
Edité par
Elsevier Science Publishing Co Inc, 2015
ISBN 10 : 0128022086
ISBN 13 : 9780128022085
Neuf
Couverture rigide
Vendeur : THE SAINT BOOKSTORE, Southport, Royaume-Uni
Évaluation du vendeur 5 sur 5 étoiles
Hardback. Etat : New. New copy - Usually dispatched within 4 working days. 1200. N° de réf. du vendeur B9780128022085
Quantité disponible : Plus de 20 disponibles
Image fournie par le vendeur
Drug Discovery in Cancer Epigenetics
Edité par
Elsevier Science Dez 2015, 2015
ISBN 10 : 0128022086
ISBN 13 : 9780128022085
Neuf
Couverture rigide
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Buch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic. 498 pp. Englisch. N° de réf. du vendeur 9780128022085
Quantité disponible : 2 disponible(s)
Image fournie par le vendeur
Drug Discovery in Cancer Epigenetics
Edité par
Elsevier Science, 2015
ISBN 10 : 0128022086
ISBN 13 : 9780128022085
Neuf
Couverture rigide
Vendeur : AHA-BUCH GmbH, Einbeck, Allemagne
Évaluation du vendeur 5 sur 5 étoiles
Buch. Etat : Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Drug Discovery in Cancer Epigenetics is a practical resource for scientists involved in the discovery, testing, and development of epigenetic cancer drugs. Epigenetic modifications can have significant implications for translational science as biomarkers for diagnosis, prognosis or therapy prediction. Most importantly, epigenetic modifications are reversible and epigenetic players are found mutated in different cancers; therefore, they provide attractive therapeutic targets. There has been great interest in developing and testing epigenetic drugs, which inhibit DNA methyltransferases, histone modifying enzymes or chromatin reader proteins. The first few drugs are already FDA approved and have made their way into clinical settings. This book provides a comprehensive summary of the epigenetic drugs currently available and aims to increase awareness in this area to foster more rapid translation of epigenetic drugs into the clinic. N° de réf. du vendeur 9780128022085
Quantité disponible : 2 disponible(s)